The FDA has approved the use of Reblozyl, or luspatercept-aamt, to treat anemia in adult patients with beta thalassemia who need frequent red blood cell transfusions, with Acceleron Pharma and partner Celgene promoting the product jointly in the US.
FDA approves Reblozyl for thalassemia-related anemia in adults
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.